Figure S4 from Clinical Efficacy and Tumor Microenvironment Influence in a Dose-Escalation Study of Anti-CD19 Chimeric Antigen Receptor T Cells in Refractory B-Cell Non-Hodgkin's Lymphoma

Supplementary Figure S4. EGFR+ and Ki67+ expression in the complete remission and partial remission patients after CAR T treatment. Immunohistochemistry of CAR T cells (EGFR+, red) and Ki67+ (brown) in tumor samples of the complete remission (CR) and partial remission (PR) patients after CAR T treatment. The cells were counted from five randomly selected visions. Bar plots showing the comparison of absolute quantification of double EGFR+Ki67+ cells.